Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Massachusetts for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Massachusetts only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Massachusetts (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Adam Feldman (NPI 1457342636)

Field	Value
Entity Type	Individual
Organization	Adam Feldman
Address	55 Fruit St
City	Boston
State	MA
ZIP	02114
Taxonomy	Urology Physician
NPI Enumerated	November 4, 2005

Payer Source	Total Paid
Medicare	$1.6M
Medicaid	$0

Key Findings

This provider’s Medicare footprint is the sole payer source on file: lifetime Medicare revenue is $1.6M and there is no Medicaid billing on file, so ADAM FELDMAN operates effectively as a single-payer (Medicare) practice in this dataset. That concentration has direct implications for reimbursement risk and contracting leverage, since Medicaid volume is absent and Medicare drives all reported revenue.

Revenue is highly concentrated in a single drug code and a narrow set of services: the precomputed top 3 Medicare codes account for 92.8% of the provider’s total Medicare revenue, with J9281 alone contributing $1.4M (87.3% of Medicare revenue). This indicates that a single therapy — Mitomycin pyelocalyceal instillation (J9281) — dominates financial performance and any changes to coverage or pricing for that code would materially affect overall revenue.

The code mix indicates a specialized uro-oncology practice oriented around intravesical therapies and cystoscopic procedures. High counts and revenue for J9281 and the presence of J9030 (BCG intravesical instillation), 51720 (intravesical anticarcinogenic instillation), plus cystoscopy codes 52000 and 52005 show repeated administration of bladder-directed chemotherapies/biologics and frequent endoscopic bladder evaluations rather than an office-based primary care mix. E/M codes such as 99214 and 99213 are present but represent a much smaller share of revenue, consistent with a procedure-driven specialty practice.

Competitive standing by code is mixed: J9281 ranks #1 of 2 providers nationally and is in the 100th percentile, yet the lifecycle note classifies its volume for that code as "typical, unremarkable volume," which suggests the national pool for that specific code is small even though this provider captures a large share of their own revenue from it. Conversely, the provider is an extreme high-volume outlier on several procedural codes—51720 ranks #12 of 1401 (99th percentile) and 74420 ranks #41 of 3813 (99th percentile)—indicating unusually high national procedural throughput for those specific services compared with peers.

Several codes show materially above-typical volumes: 51720 and 74420 are labeled "extreme outlier, far above typical national volume," while J9030 and 52332 are labeled "notably above typical national volume." These labels and ranks (for example, J9030 at #34 of 866, 96th percentile) point to a practice that performs intravesical therapy and related procedures at volumes well above most peers, which may reflect a focused clinical niche or a high local referral flow for bladder cancer care.

The provider bills very high claim counts for certain low-paid drug administration codes, which creates a characteristic reimbursement profile: for example, J9030 has 5.7K claims but only $11.4K revenue and J9281 has 5.9K claims associated with $1.4M revenue. This pattern — large numbers of drug administration claims with uneven per-claim payments — suggests routine, repeated in-office or ambulatory instillations where per-unit pricing and claim volume both shape revenue more than high E/M reimbursement.

Operationally, the mix of cystoscopy codes (52000, 52005, 52332, 52310) combined with imaging and procedural codes (74420, 76872) suggests in-house procedural capacity for endoscopic evaluation, ureteral stent placement, and retrograde urography. That procedural breadth supports a business model centered on diagnostics and recurring intravesical treatment rather than longitudinal primary care visits; the relatively modest revenue from office E/M codes (e.g., 99214 $34.6K) underscores this orientation.

The provider has long tenure in the National Provider Identifier system (NPI enumerated 2005-11-04, ~21 years ago), indicating an established presence in the market. When combined with the concentrated, high-volume procedural profile on several urology-specific codes, the tenure supports the interpretation of a stable, specialized practice with a developed referral base for bladder-directed therapies and endoscopic services.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

21 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9281	Mitomycin pyelocalyceal instillation, 1 mg	5,920	$230	$1.4M
52000	In this procedure, the provider performs an examination of the interior of the bladder, the urethra, and the ureteric openings by means of a cystourethroscope, a thin flexible or rigid tube with a…	240	$210	$51.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	340	$100	$34.6K
51720	This is a common treatment for bladder cancer. It involves instilling an anticarcinogenic agent into the bladder through a catheter. The provider leaves the agent in the bladder for a period of time…	260	$80	$19.9K
52005	The provider performs a cystourethroscopy, inspection of the interior areas of the bladder, urethra, and ureteric pelvis; he may or may not irrigate the bladder, instill fluids, or perform imaging of…	50	$270	$14.6K
J9030	BCG live intravesical instillation, 1 mg	5,700	$1	$11.4K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	80	$140	$11.2K
52332	The provider performs cystourethroscopy, the inspection of the interior of the bladder, the urethra, prostatic urethra, and ureteric openings using a cystoscope passed through the urethra and into…	60	$200	$11.1K
55700	Code deleted December 31, 2025.	50	$180	$8.3K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	90	$70	$6.6K

Showing 1–10 of 21

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Massachusetts Distribution

Adam Feldman — 6 of 20 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Massachusetts

Full comparison — all codes billed, vs. state median

21 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9281	1	10	5,920	$230	$1.4M
52000	10	240	90	$170	$17.6K
99214	2,394	15,410	110	$80	$15.6K
99215	4,857	6,360	40	$120	$8.9K
99213	5,869	13,700	70	$60	$8.8K
J9030	2	30	2,430	$1	$7.2K
52235	8	20	20	$300	$6.1K
52310	43	70	20	$250	$5.8K
99204	932	5,870	30	$120	$5.6K
55700	16	110	20	$170	$5.2K

Showing 1–10 of 21

Related Providers

Other providers that share a Tax Identification Number (TIN) with Adam Feldman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
The General Hospital Corporation	MA	General Acute Care Hospital	$0	$438M
Cambridge Public Health Commission	MA	General Acute Care Hospital	$0	$352.9M
Community Physicians Of Indiana Inc	IN	Family Medicine Physician	$0	$185M
Massachusetts General Physicians Organization Inc	MA	Dermatology Physician	$0	$60.2M
Boston Emergency Physician Foundation, Inc.	MA	Emergency Medicine Physician	$0	$24.3M
Colorado Permanente Medical Group, P.C.	CO	Internal Medicine Physician	$0	$23.2M
Cambridge Public Health Commission	MA	Clinic/Center	$0	$19.8M
Cambridge Public Health Commission	MA	General Acute Care Hospital	$0	$9M
David Reed	MA	Retina Specialist (Ophthalmology) Physician	$7.7M	$0
Torsten Wiegand	MA	Retina Specialist (Ophthalmology) Physician	$7.6M	$0

Nearby Providers

Other providers in the same ZIP code as Adam Feldman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Massachusetts Eye And Ear Infirmary	MA	General Acute Care Hospital	$0	$68.1M
Bay Cove Human Services, Inc	MA	Community/Behavioral Health Agency	$630.5K	$36.4M
Jewish Family & Children's Service	MA	Case Management Agency	$0	$12.5M
Commonwealth Of Massachusetts	MA	Case Management Agency	$0	$10.4M
Massachusetts Eye And Ear Associates, Inc.	MA	Ophthalmology Physician	$0	$6.6M
Chirag Shah	MA	Retina Specialist (Ophthalmology) Physician	$5M	$0
Miriam Englander-paschalis Ilios	MA	Retina Specialist (Ophthalmology) Physician	$4.5M	$0
Jeffrey Heier	MA	Retina Specialist (Ophthalmology) Physician	$3.6M	$0
Adam Chin	MA	Ophthalmology Physician	$3.4M	$870
Tina Cleary	MA	Retina Specialist (Ophthalmology) Physician	$2.8M	$0

Adam Feldman — Billing Profile & Reimbursement Data

Sign up for Adam Feldman — Billing Profile & Reimbursement Data policy alerts

Adam Feldman — Billing Profile & Reimbursement Data

Sign up for Adam Feldman — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References